Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laruparetigene zovaparvovec in X-linked retinitis pigmentosa (HORIZON)
NCT03316560Phase 2Active, not recruiting
- Sponsor
- Beacon Therapeutics
- Start
- Apr 2018
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of laruparetigene zovaparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by Beacon Therapeutics. Started Apr 2018; status: active, not recruiting.
02
Drugs
laruparetigene zovaparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT03316560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316560.